JP2016513704A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513704A5 JP2016513704A5 JP2016502487A JP2016502487A JP2016513704A5 JP 2016513704 A5 JP2016513704 A5 JP 2016513704A5 JP 2016502487 A JP2016502487 A JP 2016502487A JP 2016502487 A JP2016502487 A JP 2016502487A JP 2016513704 A5 JP2016513704 A5 JP 2016513704A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- peak positions
- crystalline
- powder
- ray diffraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361801112P | 2013-03-15 | 2013-03-15 | |
| US61/801,112 | 2013-03-15 | ||
| PCT/US2014/027591 WO2014152663A1 (en) | 2013-03-15 | 2014-03-14 | Crystalline forms of tyrosine kinase inhibitors and their salts |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016513704A JP2016513704A (ja) | 2016-05-16 |
| JP2016513704A5 true JP2016513704A5 (enExample) | 2017-04-13 |
Family
ID=51529961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502487A Pending JP2016513704A (ja) | 2013-03-15 | 2014-03-14 | チロシンキナーゼ阻害薬の結晶形態物及びその塩 |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US8999992B2 (enExample) |
| EP (1) | EP2970148A4 (enExample) |
| JP (1) | JP2016513704A (enExample) |
| KR (1) | KR20150142688A (enExample) |
| CN (1) | CN105377821A (enExample) |
| AU (1) | AU2014239254B2 (enExample) |
| BR (1) | BR112015022631A2 (enExample) |
| CA (1) | CA2904403A1 (enExample) |
| CL (1) | CL2015002593A1 (enExample) |
| CR (1) | CR20150560A (enExample) |
| EA (1) | EA201591684A1 (enExample) |
| GT (1) | GT201500292A (enExample) |
| HK (1) | HK1220193A1 (enExample) |
| MX (1) | MX2015012403A (enExample) |
| NI (1) | NI201500139A (enExample) |
| PE (1) | PE20151884A1 (enExample) |
| PH (1) | PH12015502110A1 (enExample) |
| SG (2) | SG10201707484UA (enExample) |
| SV (1) | SV2015005074A (enExample) |
| TN (1) | TN2015000407A1 (enExample) |
| UA (1) | UA116466C2 (enExample) |
| WO (1) | WO2014152663A1 (enExample) |
| ZA (1) | ZA201507154B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106336400A (zh) | 2008-12-08 | 2017-01-18 | 萌蒂制药国际有限公司 | 酪氨酸激酶蛋白受体拮抗剂 |
| US8999992B2 (en) | 2013-03-15 | 2015-04-07 | Vm Pharma Llc | Crystalline forms of tryosine kinase inhibitors and their salts |
| US10301271B2 (en) * | 2014-09-17 | 2019-05-28 | Purdue Pharma L.P. | Crystalline forms of tyrosine kinase inhibitors and their salts |
| US20180370926A1 (en) * | 2015-08-07 | 2018-12-27 | Purdue Pharma L.P. | Process of preparing tyrosine kinase inhibitor |
| AU2018350980C1 (en) | 2017-10-18 | 2024-12-12 | Incyte Corporation | Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-y gamma inhibitors |
| WO2019159097A1 (en) * | 2018-02-14 | 2019-08-22 | Sun Pharmaceutical Industries Limited | Crystalline polymorphic forms of acalabrutinib |
| CR20250050A (es) | 2018-09-05 | 2025-03-19 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165) |
| US12240813B2 (en) | 2020-05-19 | 2025-03-04 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| EP4486448A1 (en) | 2022-03-04 | 2025-01-08 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1062357A (en) * | 1965-03-23 | 1967-03-22 | Pfizer & Co C | Quinazolone derivatives |
| US4337341A (en) * | 1976-11-02 | 1982-06-29 | Eli Lilly And Company | 4a-Aryl-octahydro-1H-2-pyrindines |
| DE3815221C2 (de) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| RU2065438C1 (ru) | 1993-12-22 | 1996-08-20 | Институт химии природного органического сырья СО РАН | Способ получения производных 3-фенилокси-5-гидроксиантра (1,9-cd)-изоксазол-6-она |
| US6635626B1 (en) | 1997-08-25 | 2003-10-21 | Bristol-Myers Squibb Co. | Imidazoquinoxaline protein tyrosine kinase inhibitors |
| US5998463A (en) | 1998-02-27 | 1999-12-07 | Pfizer Inc | Glycogen phosphorylase inhibitors |
| US6476032B2 (en) | 1998-12-17 | 2002-11-05 | Wyeth | 2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5(6H)one derivatives |
| MXPA01012442A (es) | 1999-06-03 | 2004-09-10 | Abbott Gmbh & Co Kg | Compuestos de benzotiazinona y benzoxazinona. |
| FR2807660A1 (fr) | 2000-04-13 | 2001-10-19 | Warner Lambert Co | Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques |
| ES2275021T3 (es) | 2001-09-27 | 2007-06-01 | Smithkline Beecham Corporation | Derivados de azoxoindol como inhibidores de trk proteina quinasa para el tratamiento de cancer y dolor cronico. |
| KR20030095729A (ko) | 2002-06-14 | 2003-12-24 | 크리스탈지노믹스(주) | 2-[5-(3-카복시-4-클로로-페닐)-푸란-2-일메틸렌]-3-옥소-2,3-디하이드로-5Ｈ-티아졸로[3,2-ａ]피리미딘-6-카복실산에틸 에스테르 유도체를 포함하는 단백질 티로신포스파타제 1Ｂ 활성 억제용 약학 조성물 |
| EP1556083B1 (en) | 2002-10-08 | 2011-02-02 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by admisnistering an antibody against nerve growth factor and compositions containing the same |
| UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
| IL154370A0 (en) * | 2003-02-10 | 2003-09-17 | Chemagis Ltd | Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same |
| EP1629000B1 (en) | 2003-04-16 | 2009-02-18 | Bristol-Myers Squibb Company | Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus |
| CA2535265C (en) | 2003-08-22 | 2014-01-28 | Dendreon Corporation | Compositions and methods for the treatment of disease associated with trp-p8 expression |
| WO2008021463A2 (en) | 2006-08-15 | 2008-02-21 | Acadia Pharmaceuticals, Inc. | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
| AU2005243247B2 (en) | 2004-04-07 | 2012-03-01 | Regents Of The University Of Minnesota | Methods for treating bone cancer pain by administering a nerve growth factor antagonist |
| WO2006007864A1 (en) | 2004-07-17 | 2006-01-26 | Max Planck Geselllschaft Zur Förderung Der Wissenschaft | Treating neurodegenerative conditions |
| US7671077B2 (en) * | 2004-07-19 | 2010-03-02 | Leu-Fen Hou Lin | Neuroprotective small organic molecules, compositions and uses related thereto |
| US7718674B2 (en) | 2004-09-27 | 2010-05-18 | Bridge Pharma, Inc. | Methods of relieving neuropathic pain with the S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine |
| MX2007008771A (es) | 2005-01-19 | 2007-09-11 | Mgi Gp Inc | Compuestos de diazabenzo [des] antracen-3-ona y metodos para inhibir parp. |
| FR2881138B1 (fr) | 2005-01-27 | 2007-03-02 | Servier Lab | Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US20060257337A1 (en) | 2005-04-28 | 2006-11-16 | David Sherris | Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis |
| JP5191155B2 (ja) | 2006-03-27 | 2013-04-24 | 大塚製薬株式会社 | カルボスチリル化合物からなる医薬 |
| JP2007303392A (ja) | 2006-05-11 | 2007-11-22 | Honda Motor Co Ltd | 気体燃料内燃機関の制御装置 |
| WO2008053863A1 (en) | 2006-10-30 | 2008-05-08 | Santen Pharmaceutical Co., Ltd. | Novel compound having 1,4-benzothiazin-3-one skeleton or 3,4-dihydroquinolin-2-one skeleton |
| ES2506090T3 (es) | 2006-12-28 | 2014-10-13 | Abbvie Inc. | Inhibidores de la (ADP-ribosa) polimerasa |
| WO2009024989A2 (en) | 2007-08-17 | 2009-02-26 | Hetero Drugs Limited | A novel hydrated form of erlotinib free base and a process for preparation of erlotinib hydrochloride polymorph form a substantially free of polymorph form b |
| JP5662801B2 (ja) | 2007-11-16 | 2015-02-04 | ホリンワース ファンド，エル．エル．シー． | フィルタ設計方法およびメタマテリアル構造ベースのフィルタ |
| CN106336400A (zh) * | 2008-12-08 | 2017-01-18 | 萌蒂制药国际有限公司 | 酪氨酸激酶蛋白受体拮抗剂 |
| EP2239256A1 (en) * | 2009-03-13 | 2010-10-13 | Almirall, S.A. | Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor |
| WO2011063398A1 (en) * | 2009-11-23 | 2011-05-26 | Cylene Pharamaceuticals, Inc. | Polymorphs and salts of a kinase inhibitor |
| PH12012502495A1 (en) | 2010-06-23 | 2013-02-11 | Osi Pharmaceuticals Llc | Polymorphs of osi-906 |
| AU2012205669B2 (en) | 2011-01-10 | 2015-08-20 | Infinity Pharmaceuticals Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
| US9376406B2 (en) | 2011-03-03 | 2016-06-28 | Indiana University Research And Technology Corporation | uPAR-uPA interaction inhibitors and methods for treating cancer |
| US8999992B2 (en) | 2013-03-15 | 2015-04-07 | Vm Pharma Llc | Crystalline forms of tryosine kinase inhibitors and their salts |
| US10301271B2 (en) | 2014-09-17 | 2019-05-28 | Purdue Pharma L.P. | Crystalline forms of tyrosine kinase inhibitors and their salts |
-
2014
- 2014-03-13 US US14/208,244 patent/US8999992B2/en active Active
- 2014-03-14 MX MX2015012403A patent/MX2015012403A/es unknown
- 2014-03-14 BR BR112015022631A patent/BR112015022631A2/pt not_active IP Right Cessation
- 2014-03-14 PE PE2015002014A patent/PE20151884A1/es not_active Application Discontinuation
- 2014-03-14 EP EP14770743.4A patent/EP2970148A4/en not_active Withdrawn
- 2014-03-14 EA EA201591684A patent/EA201591684A1/ru unknown
- 2014-03-14 SG SG10201707484UA patent/SG10201707484UA/en unknown
- 2014-03-14 HK HK16108270.6A patent/HK1220193A1/zh unknown
- 2014-03-14 CA CA2904403A patent/CA2904403A1/en not_active Abandoned
- 2014-03-14 WO PCT/US2014/027591 patent/WO2014152663A1/en not_active Ceased
- 2014-03-14 CN CN201480015906.9A patent/CN105377821A/zh active Pending
- 2014-03-14 CR CR20150560A patent/CR20150560A/es unknown
- 2014-03-14 AU AU2014239254A patent/AU2014239254B2/en not_active Expired - Fee Related
- 2014-03-14 JP JP2016502487A patent/JP2016513704A/ja active Pending
- 2014-03-14 SG SG11201507516XA patent/SG11201507516XA/en unknown
- 2014-03-14 UA UAA201509781A patent/UA116466C2/uk unknown
- 2014-03-14 US US14/772,264 patent/US9718794B2/en active Active
- 2014-03-14 KR KR1020157029442A patent/KR20150142688A/ko not_active Withdrawn
-
2015
- 2015-03-02 US US14/635,635 patent/US9388146B2/en active Active
- 2015-09-10 CL CL2015002593A patent/CL2015002593A1/es unknown
- 2015-09-10 TN TN2015000407A patent/TN2015000407A1/en unknown
- 2015-09-11 NI NI201500139A patent/NI201500139A/es unknown
- 2015-09-14 PH PH12015502110A patent/PH12015502110A1/en unknown
- 2015-09-14 GT GT201500292A patent/GT201500292A/es unknown
- 2015-09-14 SV SV2015005074A patent/SV2015005074A/es unknown
- 2015-09-28 ZA ZA2015/07154A patent/ZA201507154B/en unknown
-
2016
- 2016-06-17 US US15/185,754 patent/US9993473B2/en active Active
-
2017
- 2017-07-13 US US15/648,527 patent/US10124002B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018515490A5 (enExample) | ||
| RU2014151565A (ru) | Способ получения n-[5-(3,5-дифторбензил)-1н-индазол-3-ил]-4-(4-метилпиперазин-1-ил)-2-(тетрагидропиран-4-иламино)бензамида | |
| JP2016528179A5 (enExample) | ||
| JP2014524476A5 (enExample) | ||
| CA2543650A1 (en) | A crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same | |
| RU2019101220A (ru) | Кристаллические формы соединения триазолопиримидина | |
| JP2018531280A5 (enExample) | ||
| JP2017061547A5 (enExample) | ||
| JP2013237682A5 (enExample) | ||
| HRP20201383T1 (hr) | Kruti oblici spoja za moduliranje kinaza | |
| JP2017527578A5 (enExample) | ||
| TW201348229A (zh) | 苯并噻吩化合物或其鹽類之二水合物、及其製造方法 | |
| JP2018516883A5 (enExample) | ||
| JP2016503010A5 (enExample) | ||
| JP2016539985A5 (enExample) | ||
| JP2016538344A5 (enExample) | ||
| JP2014530818A5 (enExample) | ||
| JP2019527239A5 (enExample) | ||
| JP2019516749A5 (enExample) | ||
| JP2016537326A5 (enExample) | ||
| JP2018524342A5 (enExample) | ||
| JP2015516425A5 (enExample) | ||
| JP2018503649A5 (enExample) | ||
| WO2014164648A4 (en) | Solid state forms of a quinazoline derivative and its use as a braf inhibitor | |
| RU2012136148A (ru) | Новая кристаллическая форма производного циклопропилбензамида |